We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company


  Silver Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Serum Extracellular Vesicle Arginase 1 Measured In T2DM

By LabMedica International staff writers
Posted on 18 Mar 2022
Print article
Image: The NanoSight NS300 utilizes the latest version of NanoSight’s particle characterization technology, Nanoparticle Tracking Analysis (NTA) (Photo courtesy of University of New South Wales)
Image: The NanoSight NS300 utilizes the latest version of NanoSight’s particle characterization technology, Nanoparticle Tracking Analysis (NTA) (Photo courtesy of University of New South Wales)

Type 2 diabetes mellitus (T2DM) has become one of the most pressing and prevalent epidemics in the last few decades and is associated with an increased risk of cardiovascular and cerebrovascular diseases with high mortality and disability.

Emerging evidence suggests that specific molecules derived from body fluids such as urine and blood are also closely associated with the presence of diabetes or diabetes-related diseases. As a new type of biomarker resource, extracellular vesicles (EVs) presented in accessible biofluids have garnered considerable attention due to their high stability in body fluids.

Medical Scientists at the Beijing Anzhen Hospital (Beijing, China) and their colleagues performed a cross-sectional study in 103 Chinese between the age of 32 and 89, including 73 T2DM patients and 30 non-T2DM. An overnight fasting blood sample was drawn from each participant into a serum collection tube. Serum triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and other serum biochemical indexes were measured by biochemical analyzer (Hitachi 7600, Tokyo, Japan).

After centrifugation processing, the number and size of EVs was measured by Nanoparticle Tracking Analysis with a Nanosight NS300 instrument (Malvern, UK). Serum Extracellular Vesicle Arginase 1 (EV-derived ARG 1) concentration was measured using Human Arginase 1 Simplestep ELISA Kit (Abcam, Inc., Burlingame, CA, USA), a highly sensitive enzyme-linked immunosorbent assay kit. The OD value at 450 nm was recorded by an EnSpire microplate reader (Perkin Elmer Singapore Pte. Ltd., Singapore). Chemiluminescence signals from Western Blotting were visualized using supersensitive chemiluminescent substrates (Thermo Fisher Scientific, Waltham, MA, USA) and detected by an imaging system (Bio-Rad, Hercules, CA, USA).

The investigators reported that serum EV-derived ARG 1 levels were significantly higher in T2DM patients compared with non-T2DM patients. Correlation analysis revealed that serum EV-derived ARG 1 levels were positively associated with fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c). Serum EV-derived ARG 1 levels were significantly associated with T2DM, especially in the subgroup of T2DM for more than 10 years (Odds Ratio (OR) = 1.651), after adjusting for confounding factors.

The authors concluded that their study there was a significant association between serum EV-derived ARG 1 levels and the presence and duration of T2DM. It would help explain in part that more vascular diseases occur in T2DM compared to non-T2DM. The study was published on March 11, 2022 in the journal BMC Endocrine Disorders.

Related Links:
Beijing Anzhen Hospital 
Perkin Elmer Singapore 
Thermo Fisher Scientific


Gold Supplier
SARS-CoV-2 (ORF1a, N, RdRp) Real-Time RT-PCR Test
DiaPlexQ SARS-CoV-2 (ORF1a, N, RdRp)
Benchtop Centrifuge & Vortexer
Silver Supplier
Receptor Destroying Enzyme
RDE II (Receptor Destroying Enzyme)
Platinum Supplier
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article


Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more


view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more


view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.